Literature DB >> 33524025

Generating evidence on screening, diagnosis and management of non-communicable diseases during pregnancy; a scoping review of current gap and practice in India with a comparison of Asian context.

Theophilus Lakiang1, Sonali Abner Daniel1, Kauma Kurian C1, Minashree Horo1, Shumayla Shumayla1, Sunil Mehra1.   

Abstract

BACKGROUND: Children born to high-risk pregnancies are more likely to experience adverse health outcomes later in life. As estimated, 15% of all pregnancies are at risk of various life-threatening conditions leading to adverse maternal and foetal outcomes. Millennium Development Goal resulted in the global reduction of maternal death from 390,000 to 275000 in 1990-2015). Similarly, to keep this momentum, the current United Nations Sustainable Development Goal (SDG: 3.1) aims at reducing the global maternal mortality ratio to less than 70 per 100,000 live births by 2030, and this can be achieved by addressing high-risk pregnancy contributing to significant mortality and morbidity. In India, gestational diabetes, gestational hypertension, and gestational hypothyroidism were identified as factors contributing to the high-risk pregnancy. This review summarises the commonly used approach for screening, diagnosis, and management of these conditions in the Asian population. It draws a comparison with the current protocols and guidelines in the Indian setting.
METHODS: Electronic search in PubMed and Google Scholar, reference snowballing, and review of current guidelines and protocols were done between January 2010 to October 2019. Published studies reporting Screening, diagnosis, and management of these conditions were included. Articles selected were then screened, appraised for quality, extract relevant data, and synthesised.
RESULTS: Screening, diagnosis, and management of these three conditions vary and no single universally accepted criteria for diagnosis and management exist to date. In India, national guidelines available have not been evaluated for feasibility of implementation at the community level. There are no national guidelines for PIH diagnosis and management despite the increasing burden and contribution to maternal and perinatal morbidity and mortality. Criteria for diagnosis and management of gestational diabetes, gestational hypertension, and gestational hypothyroidism varies but overall early screening for predicting risk, as reported from majority of the articles, were effective in minimizing maternal and foetal outcome.
CONCLUSION: Existing National guidelines for Screening, Diagnosis, and Management of Gestational Diabetes Mellitus (2018) and Gestational Hypothyroidism (2014) need to be contextualized and modified based on the need of the local population for effective treatment. Findings from this review show that early screening for predicting risk to be an effective preventive strategy. However, reports related to a definitive diagnosis and medical management were heterogeneous.

Entities:  

Year:  2021        PMID: 33524025      PMCID: PMC7850625          DOI: 10.1371/journal.pone.0244136

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  66 in total

1.  The glucose challenge test for screening of gestational diabetes.

Authors:  A Shrestha; C D Chawla
Journal:  Kathmandu Univ Med J (KUMJ)       Date:  2011 Apr-Jun

2.  Elevated serum βhCG and dyslipidemia in second trimester as predictors of subsequent Pregnancy Induced Hypertension.

Authors:  M P Mallick; S Ray; R Medhi; S Bisai
Journal:  Bangladesh Med Res Counc Bull       Date:  2014-12

3.  Screening for gestational diabetes mellitus in pregnant females.

Authors:  M S Ardawi; H A Nasrat; H S Jamal; H M Al-Sagaaf; B E Mustafa
Journal:  Saudi Med J       Date:  2000-02       Impact factor: 1.484

4.  Pregnancy outcome of gestational diabetes mellitus using a structured model of care : WINGS project (WINGS-10).

Authors:  Ram Uma; Balaji Bhavadharini; Harish Ranjani; Manni Mohanraj Mahalakshmi; Ranjit Mohan Anjana; Ranjit Unnikrishnan; Arivudainambi Kayal; Belma Malanda; Anne Belton; Viswanathan Mohan
Journal:  J Obstet Gynaecol Res       Date:  2016-12-27       Impact factor: 1.730

5.  PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation.

Authors:  Andrea C Tricco; Erin Lillie; Wasifa Zarin; Kelly K O'Brien; Heather Colquhoun; Danielle Levac; David Moher; Micah D J Peters; Tanya Horsley; Laura Weeks; Susanne Hempel; Elie A Akl; Christine Chang; Jessie McGowan; Lesley Stewart; Lisa Hartling; Adrian Aldcroft; Michael G Wilson; Chantelle Garritty; Simon Lewin; Christina M Godfrey; Marilyn T Macdonald; Etienne V Langlois; Karla Soares-Weiser; Jo Moriarty; Tammy Clifford; Özge Tunçalp; Sharon E Straus
Journal:  Ann Intern Med       Date:  2018-09-04       Impact factor: 25.391

6.  Soluble TNF-Like Weak Inducer of Apoptosis as a New Marker in Preeclampsia: A Pilot Clinical Study.

Authors:  Zeynep Kayaoglu Yildirim; Abdullah Sumnu; Neslihan Bademler; Elif Kilic; Gulay Sumnu; Serhat Karadag; Meltem Gursu; Aysegul Ozel; Gonca Batmaz; Seda Ates; Banu Dane; Savas Ozturk
Journal:  Dis Markers       Date:  2016-02-17       Impact factor: 3.434

7.  The CRADLE vital signs alert: qualitative evaluation of a novel device designed for use in pregnancy by healthcare workers in low-resource settings.

Authors:  Hannah L Nathan; Helena Boene; Khatia Munguambe; Esperança Sevene; David Akeju; Olalekan O Adetoro; Umesh Charanthimath; Mrutyunjaya B Bellad; Annemarie de Greeff; John Anthony; David R Hall; Wilhelm Steyn; Marianne Vidler; Peter von Dadelszen; Lucy C Chappell; Jane Sandall; Andrew H Shennan
Journal:  Reprod Health       Date:  2018-01-05       Impact factor: 3.223

8.  Efficacy of metformin in improving glycaemic control & perinatal outcome in gestational diabetes mellitus: A non-randomized study.

Authors:  Neeta Singh; Malti Madhu; Perumal Vanamail; Nisha Malik; Sunesh Kumar
Journal:  Indian J Med Res       Date:  2017-05       Impact factor: 2.375

9.  Foley catheter vs. oral misoprostol to induce labour among hypertensive women in India: a cost-consequence analysis alongside a clinical trial.

Authors:  S Leigh; P Granby; A Haycox; S Mundle; H Bracken; V Khedikar; J Mulik; B Faragher; T Easterling; M A Turner; Z Alfirevic; B Winikoff; A D Weeks
Journal:  BJOG       Date:  2018-06-22       Impact factor: 6.531

10.  Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low- and middle-income countries: a WHO secondary analysis.

Authors:  Ver Luanni Bilano; Erika Ota; Togoobaatar Ganchimeg; Rintaro Mori; João Paulo Souza
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.